Published in EMBO J on June 16, 2005
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43
Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. Mol Cell Biol (2006) 2.00
A genomic screen for activators of the antioxidant response element. Proc Natl Acad Sci U S A (2007) 1.44
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer (2010) 1.33
Requirement of TORC1 for late-phase long-term potentiation in the hippocampus. PLoS One (2006) 1.22
The coactivator CRTC1 promotes cell proliferation and transformation via AP-1. Proc Natl Acad Sci U S A (2009) 1.20
Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol (2013) 1.18
New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle (2010) 1.16
Salivary gland cancer stem cells. Oral Oncol (2013) 0.92
Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett (2008) 0.90
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. J Clin Invest (2016) 0.89
Activation of TORC1 transcriptional coactivator through MEKK1-induced phosphorylation. Mol Biol Cell (2008) 0.88
CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis. Adv Hematol (2009) 0.88
Salivary mucoepidermoid carcinoma: demonstration of transcriptionally active human papillomavirus 16/18. Head Neck Pathol (2012) 0.87
MAML2 rearrangement in primary pulmonary mucoepidermoid carcinoma and the correlation with FLT1 expression. PLoS One (2014) 0.86
CRTC1 expression during normal and abnormal salivary gland development supports a precursor cell origin for mucoepidermoid cancer. Gene Expr Patterns (2010) 0.84
Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer. J Natl Cancer Inst (2014) 0.83
Bipartite functions of the CREB co-activators selectively direct alternative splicing or transcriptional activation. EMBO J (2009) 0.81
CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement. Proc Natl Acad Sci U S A (2014) 0.81
PKCε signalling activates ERK1/2, and regulates aggrecan, ADAMTS5, and miR377 gene expression in human nucleus pulposus cells. PLoS One (2013) 0.81
Signatures of archaic adaptive introgression in present-day human populations. Mol Biol Evol (2016) 0.79
The orphan nuclear receptor NR4A2 is part of a p53-microRNA-34 network. Sci Rep (2016) 0.78
Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth. Oncogene (2015) 0.77
The MECT1-MAML2 gene fusion and benign Warthin's tumor: is the MECT1-MAML2 gene fusion specific to mucuepidermoid carcinoma? J Mol Diagn (2006) 0.77
Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. Clin Cancer Res (2016) 0.76
Molecular Basis for the Mechanism of Constitutive CBP/p300 Coactivator Recruitment by CRTC1-MAML2 and Its Implications in cAMP Signaling. Biochemistry (2015) 0.75
Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells. BMC Cancer (2015) 0.75
Mastermind-Like 1 Is Ubiquitinated: Functional Consequences for Notch Signaling. PLoS One (2015) 0.75
11q21.1-11q23.3 Is a site of intrinsic genomic instability triggered by irradiation. Genes Chromosomes Cancer (2010) 0.75
Mucoepidermoid carcinoma of the sublingual gland harboring a translocation of the MAML2 gene: A case report. Oncol Lett (2017) 0.75
Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A (2001) 68.44
Notch signaling: cell fate control and signal integration in development. Science (1999) 28.83
Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol (2001) 10.69
Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J (2002) 4.91
The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet (1996) 4.59
Id proteins in development, cell cycle and cancer. Trends Cell Biol (2003) 4.53
TORCs: transducers of regulated CREB activity. Mol Cell (2003) 4.42
A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos. Mol Cell Biol (1998) 4.26
Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells. Proc Natl Acad Sci U S A (2003) 3.21
What turns CREB on? Cell Signal (2004) 3.03
Activation of cAMP response element-mediated gene expression by regulated nuclear transport of TORC proteins. Curr Biol (2004) 2.69
Mastermind mediates chromatin-specific transcription and turnover of the Notch enhancer complex. Genes Dev (2002) 2.64
t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet (2003) 2.30
Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics. Blood (1999) 2.02
CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. Nature (2003) 1.98
Regulating the regulators: lysine modifications make their mark. Cell (2003) 1.85
Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol (2002) 1.81
Novel cyclic adenosine 3',5'-monophosphate (cAMP) response element modulator theta isoforms expressed by two newly identified cAMP-responsive promoters active in the testis. Endocrinology (2000) 1.50
Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol (2002) 1.47
AcK-knowledge reversible acetylation. Sci STKE (2004) 1.39
Recruitment of p300 by C/EBPbeta triggers phosphorylation of p300 and modulates coactivator activity. EMBO J (2003) 1.29
Fos family members: regulation, structure and role in oncogenic transformation. Histol Histopathol (2000) 1.23
Altered Notch signaling resulting from expression of a WAMTP1-MAML2 gene fusion in mucoepidermoid carcinomas and benign Warthin's tumors. Exp Cell Res (2004) 1.15
The NGFI-B subfamily of the nuclear receptor superfamily (review). Int J Oncol (1998) 1.14
Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol (2004) 1.12
A study of MECT1-MAML2 in mucoepidermoid carcinoma and Warthin's tumor of salivary glands. J Mol Diagn (2004) 1.08
Transcription factor ATF3 partially transforms chick embryo fibroblasts by promoting growth factor-independent proliferation. Oncogene (2001) 1.07
The adenovirus E1A-associated 300-kD protein exhibits properties of a transcriptional coactivator and belongs to an evolutionarily conserved family. Cold Spring Harb Symp Quant Biol (1994) 1.05
The role of cyclic-AMP binding protein (CREB) in leukemia cell proliferation and acute leukemias. Leuk Lymphoma (2004) 1.04
Oncogene activation in pituitary tumors. Brain Pathol (2001) 0.97
Specification of cell fates within the salivary gland primordium. Dev Biol (2003) 0.97
Malignant salivary gland neoplasms: a cytogenetic study of 19 cases. Eur J Cancer B Oral Oncol (1996) 0.92
The Id2 transcriptional repressor is induced by follicle-stimulating hormone and cAMP. J Biol Chem (2004) 0.86
Effects of dibutyryl cAMP on stanniocalcin and stanniocalcin-related protein mRNA expression in neuroblastoma cells. J Endocrinol (2002) 0.82
Cytogenetic characterisation of Warthin's tumour. Oral Oncol (1997) 0.79
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med (2013) 7.52
The roles of FLT3 in hematopoiesis and leukemia. Blood (2002) 6.14
HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell (2007) 6.06
Atg32 is a mitochondrial protein that confers selectivity during mitophagy. Dev Cell (2009) 5.77
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell (2010) 5.02
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A (2008) 4.79
Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol (2003) 4.43
MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res (2009) 4.32
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med (2012) 4.26
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
The interplay between MYC and HIF in cancer. Nat Rev Cancer (2008) 3.97
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A (2009) 3.76
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol (2007) 3.51
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer (2007) 3.36
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 3.09
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell (2003) 2.70
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Efficient targeted gene disruption in Xenopus embryos using engineered transcription activator-like effector nucleases (TALENs). Proc Natl Acad Sci U S A (2012) 2.53
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res (2005) 2.49
Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int (2005) 2.42
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 2.42
Next generation genome-wide association tool: design and coverage of a high-throughput European-optimized SNP array. Genomics (2011) 2.31
t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet (2003) 2.30
Pathophysiology of acute pancreatitis. Pancreatology (2005) 2.25
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood (2011) 2.23
Evaluation of the glaucomatous damage on retinal nerve fiber layer thickness measured by optical coherence tomography. Am J Ophthalmol (2003) 2.23
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood (2005) 2.14
The conserved oligomeric Golgi complex is involved in double-membrane vesicle formation during autophagy. J Cell Biol (2010) 2.12
Dissociated optic nerve fiber layer appearance after internal limiting membrane peeling for idiopathic macular holes. Ophthalmology (2005) 2.12
Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med (2015) 2.04
Legionella pneumophila inhibits macrophage apoptosis by targeting pro-death members of the Bcl2 protein family. Proc Natl Acad Sci U S A (2007) 1.96
Navigated minimally invasive presigmoidal suprabulbar infralabyrinthine approach to the jugular foramen without rerouting of the facial nerve. Neurosurgery (2013) 1.94
Optical coherence tomography detects characteristic retinal nerve fiber layer thickness corresponding to band atrophy of the optic discs. Ophthalmology (2004) 1.91
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood (2014) 1.89
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood (2007) 1.85
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood (2006) 1.83
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A (2004) 1.82
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood (2004) 1.81
Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol (2002) 1.81
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A (2004) 1.81
Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest (2009) 1.80
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res (2004) 1.79
The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis. Genes Dev (2006) 1.79
Overproduction of eukaryotic SUMO-1- and SUMO-2-conjugated proteins in Escherichia coli. Anal Biochem (2004) 1.72
The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation. Cell Metab (2005) 1.72
Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant (2005) 1.71
Sensitivity analysis of discrete stochastic systems. Biophys J (2005) 1.70
Diagnosis of bladder cancer with microelectromechanical systems-based cystoscopic optical coherence tomography. Urology (2009) 1.69
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest (2015) 1.67
Tissue-engineered breast reconstruction: bridging the gap toward large-volume tissue engineering in humans. Plast Reconstr Surg (2011) 1.63
Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) (2011) 1.62
Golgi localization of glycosyltransferases requires a Vps74p oligomer. Dev Cell (2008) 1.62
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res (2005) 1.61
Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells. Cancer Biol Ther (2006) 1.60
Quantification of retinal nerve fiber layer thickness reduction associated with a relative afferent pupillary defect in asymmetric glaucoma. Br J Ophthalmol (2006) 1.59
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood (2005) 1.58
Self-interaction is critical for Atg9 transport and function at the phagophore assembly site during autophagy. Mol Biol Cell (2008) 1.58
Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes (2006) 1.58
Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem (2003) 1.54
Natural pregnancy and delivery after allogeneic bone marrow transplantation in a Fanconi anaemia patient. Br J Haematol (2006) 1.54
Role of FLT3 in leukemia. Curr Opin Hematol (2002) 1.52
Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res (2005) 1.51
Knockdown of RCK/p54 expression by RNAi inhibits proliferation of human colorectal cancer cells in vitro and in vivo. Cancer Biol Ther (2008) 1.50
Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol (2002) 1.48
Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema. Ophthalmology (2004) 1.48
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat (2009) 1.47
Pattern recognition scavenger receptor SRA/CD204 down-regulates Toll-like receptor 4 signaling-dependent CD8 T-cell activation. Blood (2009) 1.47
Stochastic exit from mitosis in budding yeast: model predictions and experimental observations. Cell Cycle (2011) 1.46
Algorithms and software for stochastic simulation of biochemical reacting systems. Biotechnol Prog (2007) 1.45
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood (2013) 1.44
Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab (2004) 1.44
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood (2014) 1.44
The first report of successful nasogastric Coca-Cola lavage treatment for bitter persimmon phytobezoars in Japan. Am J Gastroenterol (2003) 1.44
Association of Toll-like receptor 4 gene polymorphisms with normal tension glaucoma. Invest Ophthalmol Vis Sci (2008) 1.43
Induction of the chemokine receptor CXCR3 on TCR-stimulated T cells: dependence on the release from persistent TCR-triggering and requirement for IFN-gamma stimulation. Eur J Immunol (2002) 1.42
Comparison of confocal scanning laser ophthalmoscopy, scanning laser polarimetry and optical coherence tomography to discriminate ocular hypertension and glaucoma at an early stage. Graefes Arch Clin Exp Ophthalmol (2005) 1.42
The fatty acid profile of the erythrocyte membrane in initial-onset inflammatory bowel disease patients. Dig Dis Sci (2013) 1.41
c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J Biol Chem (2013) 1.37
Nkx6.1 controls a gene regulatory network required for establishing and maintaining pancreatic Beta cell identity. PLoS Genet (2013) 1.37
Targeting eEF1A by a Legionella pneumophila effector leads to inhibition of protein synthesis and induction of host stress response. Cell Microbiol (2009) 1.36